New version of Adis R&D Insight global pipeline database launched

Wolters Kluwer Pharma Solutions, Inc., a leading provider of market data and competitive intelligence to the pharmaceutical and biotech industries, today introduced a powerful, new version of its popular Adis R&D Insight global pipeline database. Available immediately, the enhanced product quantifies probability of approval and revenue potential for thousands of drugs in development. The new Adis R&D Insight is the first research tool to become available that combines quantitative forecasting capabilities with a comprehensive collection of research on pipeline drugs.

"Many companies have been talking about the need for better products to aid the process of forecasting pipeline drugs," said Jeff Southwood, Senior Product Manager, Business Intelligence, Wolters Kluwer Pharma Solutions. "Today, we've delivered and made available one that sets a new standard by integrating forecasting with deep science."

Adis R&D Insight utilizes the intelligent forecasting of inThought, the company's pharmaceutical research service, to assign approvability ratings and generate revenue forecasts. Every active-development drug in the database is assigned an inThought Approvability Index (IAI), which assesses the progress of a drug candidate through clinical development. An evidence-based score is assigned for specific line items relating to safety, efficacy, trial design, and other factors in each phase of clinical development. InThought analysts continually update these scores based on clinical trial announcements, results, regulatory activity and other factors.

Complementing the IAI are detailed revenue models, addressing the market potential of approved drugs as well as developmental agents. Employing a proprietary model, inThought applies a consistent set of criteria across each assessment. Revenue models forecast seven years into the future and provide three years of historical data, and are developed separately for the U.S., Europe and Japan.

The new forecasting capabilities supplement a dedicated team of indication-area experts who track hundreds of developmental drugs on a daily basis by scouring published articles, conference abstracts, clinical trial registries, company websites, press releases and SEC findings, and compile findings into the database with links to key items.

A New Level of Transparency

Wolters Kluwer Pharma Solutions developed the product to provide unfettered access to the rationale behind its analysis. The current solution offers a level of transparency that is unavailable in any other pipeline product. A customer can drill-down into the source data to reveal events in the marketplace that influenced the analysis. For example, when an IAI is upgraded, a customer can link to abstracts associated with the event that led to the change.

"With this level of transparency, our clients understand how to assign value to these ratings," said Southwood.

Each IAI score also is given a second level of scrutiny in the form of a letter grade (A-F) to help verify how it compares to other drugs in the same class at a similar stage of development. This makes it easy to see the relative strength or weakness of a particular drug compared to others in its peer group.

The new forecasting features are fully integrated into the design of the product. "This approach provides greater versatility and depth of searching allowing access to every field within the database without limitation," added Southwood.

Adis R&D Insight is intended for pharma teams responsible for competitive intelligence, business development, and partnership and licensing research -- all of whom are tasked with developing their own revenue projections, market forecasts, and competitive intelligence research. Now these groups have an alternative resource to which they can compare their analysis.

Containing profiles for more than 25,000 drugs in development, Adis R&D Insight tracks and evaluates drugs worldwide through the entire development process, from discovery, through pre-clinical and clinical studies, to launch. Users can gather comprehensive drug information using customizable search criteria searchable by company, drug, indication and phase of development. Available now by subscription, learn more about the enhanced product at www.wolterskluwerpharma.com.